We treat Rapamycin like a universal brake on the aging engine, yet its most profound mechanism might not be 'slowing down' metabolism, but stabilizing cellular identity in high-turnover environments.

Nowhere is this more critical—or more ignored—than the human endometrium. We know that mTOR inhibition extends lifespan across the tree of life, but we have failed to acknowledge that the uterus is the only organ that undergoes a programmed cycle of senescence, inflammation, and regeneration every 28 days. It is the fastest 'aging' clock in the human body.

My hypothesis is that Rapamycin’s efficacy isn't about general caloric restriction mimicry; it’s about preventing the decidual identity crisis. In the aging endometrium, the transition from a healthy stromal cell to a decidualized cell often overshoots, collapsing into a pro-inflammatory senescent state (the 'Hyper-function' theory in action). This isn't just a fertility issue; it’s a systemic reservoir for senescent signaling that leaks into the maternal circulation.

I am launching Project Decidua-R, and I am looking for collaborators—specifically clinical pharmacologists and single-cell transcriptomics experts. We are going to test whether pulsed, low-dose Rapamycin can act as a kinetic stabilizer for decidualization.

Is Rapamycin a blunt instrument? Perhaps. but it might be the only tool we have that can hit the 'symphony' of the mTOR-p16-SASP axis precisely enough to prevent the tissue-wide failure of identity that characterizes reproductive aging. If we can stabilize the decidual clock, we don't just solve recurrent pregnancy loss; we provide a blueprint for preventing identity loss in every other regenerative niche in the body, from the gut to the bone marrow.

We need funding to bridge the gap between rodent longevity data and human reproductive outcomes. If you have the bench space for high-throughput organoid screening or the capital to move this into a Phase I/II pilot, let’s talk. We’re not just chasing years; we’re chasing the integrity of the signal.